{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T17:19:56Z","timestamp":1768583996701,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.urolonc.2020.08.017","type":"journal-article","created":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T10:11:11Z","timestamp":1599387071000},"page":"937.e1-937.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pushing the limits of metastasis-directed treatment in metastatic renal cell carcinoma in the era of targeted therapy"],"prefix":"10.1016","volume":"38","author":[{"given":"Serge","family":"Holz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Tosco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Akand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annelies","family":"Verbiest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Beuselinck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten","family":"Albersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Roussel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hein","family":"Van Poppel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Joniau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2020.08.017_bib0001","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2020.08.017_bib0002","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2020.08.017_bib0003","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.juro.2008.01.101","article-title":"Preoperative nomogram predicting 12-year probability of metastatic renal cancer","volume":"179","author":"Raj G","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.08.017_bib0004","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1200\/JCO.2003.02.122","article-title":"Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer","volume":"21","author":"Yang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.08.017_bib0005","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.clgc.2014.04.001","article-title":"Current practices in the management of adverse events associated with targeted therapies for advanced renal cell carcinoma: a national survey of oncologists","volume":"12","author":"Ruiz","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2020.08.017_bib0006","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","article-title":"Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial","volume":"19","author":"Atkins","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2020.08.017_bib0007","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2020.08.017_bib0008","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1016\/S1470-2045(14)70235-9","article-title":"Local treatments for metastases of renal cell carcinoma: a systematic review","volume":"15","author":"Dabestani","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2020.08.017_bib0009","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.euo.2018.08.028","article-title":"Surgical metastasectomy in renal cell carcinoma: a systematic review","volume":"2","author":"Ouzaid","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2020.08.017_bib0010","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/jso.24327","article-title":"Complete metastasectomy for renal cell carcinoma: comparison of five solid organ sites","volume":"114","author":"Jakubowski","year":"2016","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.urolonc.2020.08.017_bib0011","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.juro.2016.07.079","article-title":"Outcomes following complete surgical metastasectomy for patients with metastatic renal cell carcinoma: a systematic review and meta-analysis","volume":"197","author":"Zaid","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.08.017_bib0012","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.eururo.2015.01.005","article-title":"EAU guidelines on renal cell carcinoma: 2014 update","volume":"67","author":"Ljungberg","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.08.017_bib0013","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2020.08.017_bib0014","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2020.08.017_bib0015","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.eururo.2017.06.012","article-title":"Systematic Review of Immune Checkpoint Inhibition in Urological Cancers","volume":"72","author":"Rijnders","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.08.017_bib0016","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2020.08.017_bib0017","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.eururo.2012.09.037","article-title":"Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma","volume":"63","author":"Tosco","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.08.017_bib0018","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/21681805.2018.1553893","article-title":"Surgery for metastases of renal cell carcinoma: outcome of treatments and preliminary assessment of Leuven-Udine prognostic groups in the targeted therapy era","volume":"52","author":"Tornberg","year":"2018","journal-title":"Scand J Urol"},{"key":"10.1016\/j.urolonc.2020.08.017_bib0019","first-page":"1","article-title":"The significance of metastasectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy","volume":"2015","author":"Yu","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.urolonc.2020.08.017_bib0020","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.eururo.2018.01.042","article-title":"Molecular subtypes of clear-cell renal cell carcinoma are prognostic for outcome after complete metastasectomy","volume":"74","author":"Verbiest","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.08.017_bib0021","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"379","author":"M\u00e9jean","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2020.08.017_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(14)71222-7","article-title":"The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study","volume":"16","author":"Ko","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2020.08.017_bib0023","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1016\/S1470-2045(13)70569-2","article-title":"Radiotherapy for renal-cell carcinoma","volume":"15","author":"De Meerleer","year":"2014","journal-title":"Lancet Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920303835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920303835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T14:48:23Z","timestamp":1608302903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920303835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1078143920303835"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.08.017","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pushing the limits of metastasis-directed treatment in metastatic renal cell carcinoma in the era of targeted therapy","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}